iCoat Medical AB

iCoat Medical AB is a clinical stage, immunotherapy company based in Sweden. The company is dedicated to reducing and preventing ischemia reperfusion injuries through the development of innovative pharmaceutical products. iCoat Medical has positioned itself as one of the world's leading R&D-centered organizations within innate immunology and continues to expand its pipeline using its proprietary coating-technology platform. The lead candidate, TUM012, aims to enhance the outcomes of organ transplantations. With operations in Uppsala, Lund, and Malmö, iCoat Medical is headquartered in Stockholm. The company's unique ex-vivo coating of the grafts demonstrates the ambition to play an integral role in future transplant procedures. Despite being founded in 2018, iCoat Medical's efforts and focus on addressing critical medical needs, particularly in the field of ischemia reperfusion injuries, have garnered attention. Although details about the last investment and investors are not available at present, iCoat Medical's approach and potential impact on addressing significant medical challenges make it an intriguing prospect for venture capital considering investment opportunities in the biotech and pharmaceutical industries.